Posted by Michael Wonder on 11 Dec 2018
Glatect added to public drug plan in British Columbia as sole RRMS treatment of its type
11 December 2018 - Pendopharm’s Glatect (glatiramer acetate) — a treatment for patients with relapsing-remitting multiple sclerosis — has been added to the public drug plan in the Canadian province of British Columbia, and is now the only glatiramer-based treatment for RRMS patients there using the plan.
After Copaxone (glatiramer acetate, marketed by Teva Pharmaceuticals), Glatect is the first commercialized glatiramer-based medicine in Canada, and now available via prescription plans in seven provinces. Pendopharm, which is a division of Pharmascience in Montreal, launched the therapy in September 2017 as a lower-cost alternative to Copaxone.
Glatect has been the sole glatiramer-based treatment approved by PharmaCare Special Authority in British Columbia for requests or renewals of such treatment since 27 November.
